Your browser doesn't support javascript.
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders.
Verschuuren, Jan Jgm; Palace, Jacqueline; Murai, Hiroyuki; Tannemaat, Martijn R; Kaminski, Henry J; Bril, Vera.
  • Verschuuren JJ; Department of Neurology, Leiden University Medical Centre, Leiden, Netherlands. Electronic address: j.j.g.m.verschuuren@lumc.nl.
  • Palace J; Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK.
  • Murai H; Department of Neurology, International University of Health and Welfare, Narita, Japan.
  • Tannemaat MR; Department of Neurology, Leiden University Medical Centre, Leiden, Netherlands.
  • Kaminski HJ; Department of Neurology and Rehabilitation Medicine, The George Washington University School of Medicine & Health Sciences, Washington, DC, USA.
  • Bril V; Department of Medicine, University of Toronto, Toronto, ON, Canada.
Lancet Neurol ; 21(2): 189-202, 2022 02.
Article in English | MEDLINE | ID: covidwho-1625864
ABSTRACT
Myasthenia gravis and Lambert-Eaton myasthenic syndrome are antibody-mediated autoimmune diseases of the neuromuscular junction that usually present with weakness in ocular muscles and in proximal muscles of the limb and trunk. Prognosis regarding muscle strength, functional abilities, quality of life, and survival is generally good. However, some patients do not respond to treatment. Symptomatic drugs, corticosteroids, and steroid-sparing immunosuppressive drugs remain the cornerstone of treatment. In the past few years, new biological agents against complement, the FcRn receptor, or B-cell antigens have been tested in clinical trials. These new therapies extend the possibilities for targeted immunotherapies and promise exciting new options with a relatively rapid mode of action. Challenges in their use might occur, with barriers due to an increase in cost of care and additional considerations in the choice of drugs, and potential consequences of infection and vaccination due to the COVID-19 pandemic.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Neuromuscular Junction Diseases Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Lancet Neurol Journal subject: Neurology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Neuromuscular Junction Diseases Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Lancet Neurol Journal subject: Neurology Year: 2022 Document Type: Article